|
1
|
Webb PM and Jordan SJ: Global epidemiology
of epithelial ovarian cancer. Nat Rev Clin Oncol. 21:389–400. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lheureux S, Braunstein M and Oza AM:
Epithelial ovarian cancer: Evolution of management in the era of
precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI
|
|
3
|
Roett MA and Evans P: Ovarian cancer: An
overview. Am Fam Physician. 80:609–616. 2009.PubMed/NCBI
|
|
4
|
Geisler JP and Geisler HE: Brain
metastases in epithelial ovarian carcinoma. Gynecol Oncol.
57:246–249. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marchetti C, Ferrandina G, Cormio G,
Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A,
Mammoliti S, et al: Brain metastases in patients with EOC:
Clinico-pathological and prognostic factors. A multicentric
retrospective analysis from the MITO group (MITO 19). Gynecol
Oncol. 143:532–538. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bahat Z, Cakmak VA and Cakir E: Brain
metastasis from ovarian carcinoma: Analysis of eight cases from a
single radiotherapy center. Taiwan J Obstet Gynecol. 59:711–717.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Piura E and Piura B: Brain metastases from
ovarian carcinoma. ISRN Oncol. 2011:5274532011.PubMed/NCBI
|
|
8
|
Pope WB: Brain metastases: Neuroimaging.
Handb Clin Neurol. 149:89–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng L and Zhang J: Survival analysis of
ovarian cancer patients with distant metastasis after chemotherapy:
A SEER-based study. Indian J Cancer. 15:10.4103/ijc.IJC_175_20.
2023.PubMed/NCBI
|
|
10
|
Ogawa K, Yoshii Y, Aoki Y, Nagai Y,
Tsuchida Y, Toita T, Kakinohana Y, Tamaki W, Iraha S, Adachi G, et
al: Treatment and prognosis of brain metastases from gynecological
cancers. Neurol Med Chir (Tokyo). 48:57–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mayer RJ, Berkowitz RS and Griffiths CT:
Central nervous system involvement by ovarian carcinoma: A
complication of prolonged survivial with metastatic disease.
Cancer. 41:776–783. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Larson DM, Copeland LJ, Moser RP, Malone
JM Jr, Gershenson DM and Wharton JT: Central nervous system
metastases in epithelial ovarian carcinoma. Obstet Gynecol.
68:746–750. 1986.PubMed/NCBI
|
|
13
|
Kolomainen DF, Larkin JM, Badran M, A'Hern
RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd
JH, et al: Epithelial ovarian cancer metastasizing to the brain: A
late manifestation of the disease with an increasing incidence. J
Clin Oncol. 20:982–986. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen YL, Cheng WF, Hsieh CY and Chen CA:
Brain metastasis as a late manifestation of ovarian carcinoma. Eur
J Cancer Care (Engl). 20:44–49. 2011.PubMed/NCBI
|
|
15
|
Barker GH, Orledge J and Wiltshaw E:
Involvement of the central nervous system in patients with ovarian
carcinoma. Br J Obstet Gynaecol. 88:690–694. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Budd GT, Webster KD, Reimer RR, Martimbeau
P and Livingston RB: Treatment of advanced ovarian cancer with
cisplatin, adriamycin, and cyclophosphamide: Effect of treatment
and incidence of intracranial metastases. J Surg Oncol. 24:192–195.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stein M, Steiner M, Klein B, Beck D, Atad
J, Kuten A, Robinson E and Goldsher D: Involvement of the central
nervous system by ovarian carcinoma. Cancer. 58:2066–2069. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dauplat J, Nieberg RK and Hacker NF:
Central nervous system metastases in epithelial ovarian carcinoma.
Cancer. 60:2559–2562. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ziegler J, Gliedman P, Fass D, Beckman M,
Neophytides A and Steinfeld A: Brain metastases from ovarian
cancer. J Neurooncol. 5:211–215. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ross WM, Carmichael JA and Shelley WE:
Advanced carcinoma of the ovary with central nervous system
relapse. Gynecol Oncol. 30:398–406. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hardy JR and Harvey VJ: Cerebral
metastases in patients with ovarian cancer treated with
chemotherapy. Gynecol Oncol. 33:296–300. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Piura B, Glezerman M, Galper Y, Segal S
and Cohen Y: Brain metastases in epithelial ovarian carcinoma; two
case reports. Eur J Obstet Gynecol Reprod Biol. 36:203–208. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Plaxe SC, Dottino PR, Lipsztein R, Dalton
J and Cohen CJ: Clinical features and treatment outcome of patients
with epithelial carcinoma of the ovary metastatic to the central
nervous system. Obstet Gynecol. 75:278–281. 1990.PubMed/NCBI
|
|
24
|
LeRoux PD, Berger MS, Elliott JP and
Tamimi HK: Cerebral metastases from ovarian carcinoma. Cancer.
67:2194–2199. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodriguez GC, Soper JT, Berchuck A, Oleson
J, Dodge R, Montana G and Clarke-Pearson DL: Improved palliation of
cerebral metastases in epithelial ovarian cancer using a combined
modality approach including radiation therapy, chemotherapy, and
surgery. J Clin Oncol. 10:1553–1560. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bruzzone M, Campora E, Chiara S, Giudici
S, Merlini L, Simoni C, Mammoliti S, Rubagotti A and Rosso R:
Cerebral metastases secondary to ovarian cancer: Still an unusual
event. Gynecol Oncol. 49:37–40. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Salvati M and Cervoni L: Solitary cerebral
metastasis from ovarian carcinoma: Report of 4 cases. J Neurooncol.
19:75–77. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cormio G, Maneo A, Parma G, Pittelli MR,
Miceli MD and Bonazzi C: Central nervous system metastases in
patients with ovarian carcinoma. A report of 23 cases and a
literature review. Ann Oncol. 6:571–574. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki M, Tsukagoshi S, Ohwada M, Koumura
Y and Sato I: A patient with brain metastasis from ovarian cancer
who showed complete remission after multidisciplinary treatment.
Gynecol Oncol. 74:483–486. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kaminsky-Forrett MC, Weber B, Conroy T and
Spaëth D: Brain metastases from epithelial ovarian carcinoma. Int J
Gynecol Cancer. 10:366–371. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sanderson A, Bonington SC, Carrington BM,
Alison DL and Spencer JA: Cerebral metastasis and other cerebral
events in women with ovarian cancer. Clin Radiol. 57:815–819. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Anupol N, Ghamande S, Odunsi K, Driscoll D
and Lele S: Evaluation of prognostic factors and treatment
modalities in ovarian cancer patients with brain metastases.
Gynecol Oncol. 85:487–492. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pothuri B, Chi DS, Reid T, Aghajanian C,
Venkatraman E, Alektiar K, Bilsky M and Barakat RR: Craniotomy for
central nervous system metastases in epithelial ovarian carcinoma.
Gynecol Oncol. 87:133–137. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kumar L, Barge S, Mahapatra AK, Thulkar S,
Rath GK, Kumar S, Mishra R, Dawar R and Singh R: Central nervous
system metastases from primary epithelial ovarian cancer. Cancer
Control. 10:244–253. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cohen ZR, Suki D, Weinberg JS, Marmor E,
Lang FF, Gershenson DM and Sawaya R: Brain metastases in patients
with ovarian carcinoma: Prognostic factors and outcome. J
Neurooncol. 66:313–325. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tay SK and Rajesh H: Brain metastases from
epithelial ovarian cancer. Int J Gynecol Cancer. 15:824–829. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pectasides D, Aravantinos G, Fountzilas G,
Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D,
Economopoulos T and Dimopoulos MA: Brain metastases from epithelial
ovarian cancer. The Hellenic cooperative oncology group (HeCOG)
experience and review of the literature. Anticancer Res.
25:3553–3558. 2005.PubMed/NCBI
|
|
38
|
D'Andrea G, Roperto R, Dinia L, Caroli E,
Salvati M and Ferrante L: Solitary cerebral metastases from ovarian
epithelial carcinoma: 11 cases. Neurosurg Rev. 28:120–123. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen PG, Lee SY, Barnett GH, Vogelbaum MA,
Saxton JP, Fleming PA and Suh JH: Use of the radiation therapy
oncology group recursive partitioning analysis classification
system and predictors of survival in 19 women with brain metastases
from ovarian carcinoma. Cancer. 104:2174–2180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kastritis E, Efstathiou E, Gika D, Bozas
G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA and
Bamias A: Brain metastases as isolated site of relapse in patients
with epithelial ovarian cancer previously treated with platinum and
paclitaxel-based chemotherapy. Int J Gynecol Cancer. 16:994–999.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim TJ, Song S, Kim CK, Kim WY, Choi CH,
Lee JH, Lee JW, Bae DS and Kim BG: Prognostic factors associated
with brain metastases from epithelial ovarian carcinoma. Int J
Gynecol Cancer. 17:1252–1257. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee YK, Park NH, Kim JW, Song YS, Kang SB
and Lee HP: Gamma-knife radiosurgery as an optimal treatment
modality for brain metastases from epithelial ovarian cancer.
Gynecol Oncol. 108:505–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sehouli J, Pietzner K, Harter P, Münstedt
K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D,
Buehling KJ, et al: Prognostic role of platinum sensitivity in
patients with brain metastases from ovarian cancer: Results of a
German multicenter study. Ann Oncol. 21:2201–2205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cormio G, Loizzi V, Falagario M, Lissoni
AA, Resta L and Selvaggi LE: Changes in the management and outcome
of central nervous system involvement from ovarian cancer since
1994. Int J Gynaecol Obstet. 114:133–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Keskin S, Küçücük S, Ak N, Atalar B, Sarı
M, Sozen H, Ibis K, Topuz S and Saip P: Survival impact of optimal
surgical cytoreduction in recurrent epithelial ovarian cancer with
brain metastasis. Oncol Res Treat. 42:101–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gadducci A, Tana R, Teti G, Fanucchi A,
Pasqualetti F, Cionini L and Genazzani AR: Brain recurrences in
patients with ovarian cancer: Report of 12 cases and review of the
literature. Anticancer Res. 27:4403–4409. 2007.PubMed/NCBI
|
|
47
|
Zhang Z, Xu M, Sakandar A, Du X, He H, He
W, Li D and Wen Q: Successful treatment of a patient with brain
metastasis from ovarian cancer with BRCA wild type using niraparib:
A case report and review of the literature. Front Oncol.
12:8731982022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Heimans JJ, Vermorken JB, Wolbers JG,
Eeltink CM, Meijer OW, Taphoorn MJ and Beijnen JH: Paclitaxel
(Taxol) concentrations in brain tumor tissue. Ann Oncol. 5:951–953.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fortin D, Gendron C, Boudrias M and Garant
MP: Enhanced chemotherapy delivery by intraarterial infusion and
blood-brain barrier disruption in the treatment of cerebral
metastasis. Cancer. 109:751–760. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Takano M, Tsuda H and Sugiyama T: Clear
cell carcinoma of the ovary: Is there a role of histology-specific
treatment? J Exp Clin Cancer Res. 31:532012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
O'Brien ME, Schofield JB, Tan S, Fryatt I,
Fisher C and Wiltshaw E: Clear cell epithelial ovarian cancer
(mesonephroid): bad prognosis only in early stages. Gynecol Oncol.
49:250–254. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Omura GA, Brady MF, Homesley HD, Yordan E,
Major FJ, Buchsbaum HJ and Park RC: Long-term follow-up and
prognostic factor analysis in advanced ovarian carcinoma: The
gynecologic oncology group experience. J Clin Oncol. 9:1138–1150.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Goff BA, de la Cuesta RS, Muntz HG,
Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer
BE and Fuller AF Jr: Clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy in stage III disease. Gynecol Oncol.
60:412–417. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Itamochi H, Kigawa J, Akeshima R, Sato S,
Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M and
Terakawa N: Mechanisms of cisplatin resistance in clear cell
carcinoma of the ovary. Oncology. 62:349–353. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Itamochi H, Kigawa J and Terakawa N:
Mechanisms of chemoresistance and poor prognosis in ovarian clear
cell carcinoma. Cancer Sci. 99:653–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cabitza E, Pirola M, Baldessari C,
Bernardelli G, Zunarelli E, Pipitone S, Vitale MG, Nasso C,
Molinaro E, Oltrecolli M, et al: Cerebellar metastasis of ovarian
cancer: A case report. J Med Case Rep. 17:5532023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Alizzi Z, Roxburgh P, Cartwright D,
McLaren A, Park S, Jones R, Greening S, Hudson E, Green C, Gray S,
et al: Description of a retrospective cohort of epithelial ovarian
cancer patients with brain metastases: Evaluation of the role of
PARP inhibitors in this setting. J Clin Med. 12:24972023.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sun K, Mikule K, Wang Z, Poon G,
Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S and Wang J:
A comparative pharmacokinetic study of PARP inhibitors demonstrates
favorable properties for niraparib efficacy in preclinical tumor
models. Oncotarget. 9:37080–37096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang Q, Zhang F, Gao H and Xu Y:
Successful treatment of a patient with brain metastases from
endometrial cancer using Niraparib: A case report. Ann Palliat Med.
10:818–827. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Proskuriakova E, Aryal B, Khan S, Sanchez
D, Moss J and Khosla P: Niraparib maintenance therapy for brain
metastasis in ovarian endometrioid adenocarcinoma with peritoneal
carcinomatosis: A comprehensive case study and literature review.
Cureus. 16:e613552024.PubMed/NCBI
|
|
61
|
Liu J, Berchuck A, Backes FJ, Cohen J,
Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, et
al: NCCN Guidelines® insights: Ovarian cancer/fallopian
tube cancer/primary peritoneal cancer, version 3.2024. J Natl Compr
Canc Netw. 22:512–519. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Olivares-Urbano MA, Griñán-Lisón C,
Marchal JA and Núñez MI: CSC radioresistance: A therapeutic
challenge to improve radiotherapy effectiveness in cancer. Cells.
9:16512020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vilalta M, Rafat M and Graves EE: Effects
of radiation on metastasis and tumor cell migration. Cell Mol Life
Sci. 73:2999–3007. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tommelein J, De Vlieghere E, Verset L,
Melsens E, Leenders J, Descamps B, Debucquoy A, Vanhove C, Pauwels
P, Gespach CP, et al: Radiotherapy-Activated cancer-associated
fibroblasts promote tumor progression through paracrine igf1r
activation. Cancer Res. 78:659–670. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pietzner K, Oskay-Oezcelik G, El Khalfaoui
K, Boehmer D, Lichtenegger W and Sehouli J: Brain metastases from
epithelial ovarian cancer: Overview and optimal management.
Anticancer Res. 29:2793–2798. 2009.PubMed/NCBI
|
|
66
|
Mukai Y and Ueno H: Establishment and
implementation of cancer genomic medicine in Japan. Cancer Sci.
112:970–977. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Naito Y, Aburatani H, Amano T, Baba E,
Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, et al:
Clinical practice guidance for next-generation sequencing in cancer
diagnosis and treatment (edition 2.1). Int J Clin Oncol.
26:233–283. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Oda K, Tanikawa M, Sone K, Mori-Uchino M,
Osuga Y and Fujii T: Recent advances in targeting DNA repair
pathways for the treatment of ovarian cancer and their clinical
relevance. Int J Clin Oncol. 22:611–618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
DiSilvestro P, Banerjee S, Colombo N,
Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet
A, Leary A, et al: Overall survival with maintenance olaparib at a
7-year follow-up in patients with newly diagnosed advanced ovarian
cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol.
41:609–617. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yaghmour G, Prouet P, Wiedower E, Jamy OH,
Feldman R, Chandler JC, Pandey M and Martin MG: Genomic alterations
in neuroendocrine cancers of the ovary. J Ovarian Res. 9:522016.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Meagher NS, Schuster K, Voss A, Budden T,
Pang CNI, deFazio A, Ramus SJ and Friedlander ML: Does the primary
site really matter? Profiling mucinous ovarian cancers of uncertain
primary origin (MO-CUP) to personalise treatment and inform the
design of clinical trials. Gynecol Oncol. 150:527–533. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Du ZH, Bi FF, Wang L and Yang Q:
Next-generation sequencing unravels extensive genetic alteration in
recurrent ovarian cancer and unique genetic changes in
drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med.
6:638–647. 2018. View Article : Google Scholar : PubMed/NCBI
|
